Herbert Yang
杨昆
Herbert Yang (杨昆) is a partner at Gaorong Ventures, where he focuses on healthcare investments. Per 暗涌Waves, he has described the firm's strategy as targeting early-stage companies with "genuinely global-level innovation," spanning breakthrough medical devices, drug molecules or platform technologies addressing real clinical needs, and life-science applications in synthetic biology and agricultural tech . His deal involvement includes Kailan Pharma, Viva Biotech, Andao Pharma, and Pulnovo Medical . He was named among the top 20 healthcare investors in 2023 and again in 2025 . elsewhere's corpus does not cover his background prior to Gaorong or personal biographical details.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
高榕创投·Pulnovo Medical closes nearly $100 million Series C, setting a new Asia-Pacific record for medical device financing
A pioneer in China's original medical device innovation.
高榕创投·"These 130 unfamiliar faces look exactly like the masters of the future."
Notes from a conference where you can add 130 important contacts.
暗涌Waves·Healthcare and chip companies close new funding rounds; satellite communications, energy storage batteries, and other sectors hit milestones | Rongbao · July
Foresight and courage.
高榕创投·Chip companies, surgical robots, and consumer tech brands close new funding rounds | Rongbao · June
Notable developments to watch in June.
高榕创投·Kailan Pharma Closes Oversubscribed Series A Financing of Over 100 Million RMB to Advance Innovative Drug Development in Cholesterol Metabolism
Gaorong Ventures led the round.
高榕创投·Conversations with 29 Tech Investors: There Are Treasures, But No Treasure Map
Investing in tech is definitely the right call, but consensus remains scarce.
暗涌Waves·Pulnovo Medical Closes New Tens-of-Millions USD Funding Round to Accelerate Global Expansion
It secured a foothold in global markets and made substantial headway on multiple fronts in 2022.
高榕创投·Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
高榕创投·How AI and High-Performance Computing Give Medical Innovation "Superpowers" | Ronghui X NVIDIA Inception Program
Transforming healthcare, revolutionizing people's lives.
高榕创投·Viva Biotech Completes Nearly RMB 300 Million Series B Funding Round to Accelerate Industrialization of 3D Cell "Smart Manufacturing"
Gaorong Ventures co-led the round.
高榕创投·Medtech Entrepreneurship Is a "Game for the Brave": How to Sharpen Innovation, Product, and Organizational Capabilities | Ronghui
Discussing trends in medical technology innovation and upgrading R&D team organizational management.
高榕创投·Hangzhou Andao Pharma Closes $50 Million Series B to Advance Drug Development for Kidney Disease and Cancer
Addressing the enormous unmet clinical needs in nephrology and oncology.
高榕创投·Gaorong Bulletin · September | Gaorong Ventures Ranks Top 3 in 2021 VC Fund Returns, Milestones for Cross-Border Services, New Drug R&D, and New Brands
Consumer investment is returning to natural consumer demand, and medical technology innovation is emerging.
高榕创投·Pulmonary Hypertension Technology Developer Pulnovo Medical Raises Over 100 Million Yuan in Funding
China's first cardiovascular company in the pulmonary hypertension space to receive FDA Breakthrough Device designation.
高榕创投·
